Tratamiento de la colitis ulcerosa corticorrefractaria con infliximab

https://doi.org/10.1016/S0210-5705(03)70344-6Get rights and content

Biblografía (7)

There are more references available in the full text version of this article.

Cited by (5)

  • Colectomy rate in acute severe ulcerative colitis in the infliximab era

    2008, Digestive and Liver Disease
    Citation Excerpt :

    This figure is similar to that reported in clinical trials but a clinically relevant question concerns the potential role of infliximab in reducing the long-term colectomy rate. In the literature, the overall colectomy rate, following infliximab treatment in severe UC, ranges from 0% to 75% [23,24,26,27,32–44]. Several factors could account for this wide range, such as patient selection, definition of severity, number of infliximab infusions, geographic areas, study design, and duration of follow-up.

  • Infliximab in ulcerative colitis

    2008, Biologics: Targets and Therapy
  • Systematic review: Infliximab therapy in ulcerative colitis

    2007, Alimentary Pharmacology and Therapeutics
View full text